Rhythm Pharmaceuticals (RYTM) said late Thursday it has reacquired rights to its Imcivree obesity medication throughout mainland China, Hong Kong and Macau after terminating its 2021 licensing deal with RareStone Group.
As part of the agreement to regain the global franchise for Imcivree, Rhythm said it will repay $6.3 million in cash to RareStone and return all RareStone shares acquired under the original deal with no additional consideration.
Rhythm is also expecting to report topline data from clinical testing of Imcivree now underway in North America, Europe and Japan in patients with acquired hypothalamic obesity during Q2, it added.
Shares of the company were up 1.4% in recent after-hours activity.
Price: 55.00, Change: +0.77, Percent Change: +1.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.